Research
Ending Medicaid coverage for weight-loss drugs linked to sharp drop in GLP-1 use
The Brief
- Medicaid prescriptions for GLP-1 medications approved for weight loss fell sharply after four states ended coverage of the drugs.
- A new study led by researchers at the University of Pittsburgh reports the findings, published in JAMA.
- The study says state coverage decisions can noticeably change how many people use these medications.
Why it matters
It shows that state Medicaid coverage rules can measurably change access to GLP-1 weight-loss drugs, which matters for anyone assessing health policy or patient access.
Who’s affected
- health policy researchers
- state Medicaid program administrators
- Medicaid enrollees who use GLP-1 medications
- #glp-1
- #medicaid
- #obesity
- #health policy
- #drug coverage
Medicaid prescriptions for weight loss–approved GLP-1 medications fell sharply after four states ended coverage of the drugs, according to a new study led by researchers at the University of Pittsburgh. The findings, published in JAMA, demonstrate how state coverage decisions can…